https://www.opko.com/investors/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_b4e6ff6ef47dceb9694bce8228582222/opko/files/theme/images/logo-sm.png /investors Equisolve Investor Relations Suite https://www.opko.com/investors/news-events/press-releases/detail/545/opko-health-expands-nicoya-agreement-to-support-rayaldee-commercialization-in-greater-china Thu, 30 Apr 26 08:30:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/545/opko-health-expands-nicoya-agreement-to-support-rayaldee-commercialization-in-greater-china https://www.opko.com/investors/news-events/press-releases/detail/544/bioreference-launches-bioreference-direct-expanding-access-to-consumer-initiated-diagnostic-testing-through-a-fully-integrated-digital-platform Thu, 30 Apr 26 08:00:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/544/bioreference-launches-bioreference-direct-expanding-access-to-consumer-initiated-diagnostic-testing-through-a-fully-integrated-digital-platform https://www.opko.com/investors/news-events/press-releases/detail/543/opko-health-reports-first-quarter-2026-business-highlights-and-financial-results Tue, 28 Apr 26 16:05:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/543/opko-health-reports-first-quarter-2026-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/542/opko-healths-modex-therapeutics-begins-clinical-trial-of-tetraspecific-antibody-for-treatment-of-b-cell-lymphomas Wed, 22 Apr 26 08:00:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/542/opko-healths-modex-therapeutics-begins-clinical-trial-of-tetraspecific-antibody-for-treatment-of-b-cell-lymphomas https://www.opko.com/investors/news-events/press-releases/detail/541/opko-health-to-report-first-quarter-2026-financial-results-on-april-28-2026 Tue, 21 Apr 26 16:05:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/541/opko-health-to-report-first-quarter-2026-financial-results-on-april-28-2026 https://www.opko.com/investors/news-events/press-releases/detail/540/opko-healths-modex-therapeutics-initiates-clinical-trial-of-mdx2301-for-the-prevention-of-covid-19 Wed, 08 Apr 26 08:00:00 -0400 https://www.opko.com/investors/news-events/press-releases/detail/540/opko-healths-modex-therapeutics-initiates-clinical-trial-of-mdx2301-for-the-prevention-of-covid-19 https://www.opko.com/investors/news-events/press-releases/detail/539/opko-health-to-participate-in-the-jefferies-biotech-on-the-beach-summit Fri, 27 Feb 26 08:00:00 -0500 https://www.opko.com/investors/news-events/press-releases/detail/539/opko-health-to-participate-in-the-jefferies-biotech-on-the-beach-summit https://www.opko.com/investors/news-events/press-releases/detail/538/opko-health-reports-fourth-quarter-2025-business-highlights-and-financial-results Thu, 26 Feb 26 16:05:00 -0500 https://www.opko.com/investors/news-events/press-releases/detail/538/opko-health-reports-fourth-quarter-2025-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/537/opko-health-to-report-fourth-quarter-2025-financial-results-on-february-26 Thu, 12 Feb 26 08:00:00 -0500 https://www.opko.com/investors/news-events/press-releases/detail/537/opko-health-to-report-fourth-quarter-2025-financial-results-on-february-26 https://www.opko.com/investors/news-events/press-releases/detail/536/opko-health-and-entera-bio-expand-partnership-to-advance-first-in-class-oral-long-acting-pth-tablet-for-patients-with-hypoparathyroidism Wed, 04 Feb 26 08:00:00 -0500 https://www.opko.com/investors/news-events/press-releases/detail/536/opko-health-and-entera-bio-expand-partnership-to-advance-first-in-class-oral-long-acting-pth-tablet-for-patients-with-hypoparathyroidism